Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ANNX with free AI briefings, catalyst countdowns, and dilution alerts.

ANNX · Annexon, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$213.4M Cash on Hand
13.2mo Cash Runway
16.1% Short Interest
$17 Analyst Target (7)
Follow ANNX by email Get an email when ANNX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ANNX, unsubscribe in one click. Privacy

📣 What ANNX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
ANX005 Guillain-Barre Syndrome Phase 3 · NCT04701164 Completed
Tanruprubart Guillain-Barre Syndrome Phase 3 · NCT07020819 Recruiting
Vonaprument Geographic Atrophy Phase 3 · NCT06510816 Active not recruiting
ANX007 Geographic Atrophy Phase 2 · NCT04656561 Completed
ANX009 Lupus Nephritis Phase 1 · NCT05780515 Completed
ANX105 Healthy Phase 1 · NCT05288881 Completed
ANX1502 Healthy Phase 1 · NCT05521269 Completed
Immunoglobulin Guillain-Barré Syndrome Phase 1 · NCT04035135 Completed
IVIg Safety and Tolerability in Healthy Volunteers Phase 1 · NCT03010046 Terminated

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ANNX holds $213.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $48.3M/quarter from operations, an estimated runway of 13.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 38 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ANNX files for a raise →

👥 Who Owns ANNX

Insiders 30.3% Institutions 69.7% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 26,289,000 68.17% 2026-09-30
Redmile Group, LLC Institution (13G, 5%+) 17,918,459 46.46% 2026-07-01
BlackRock, Inc. Institution (13G, 5%+) 13,128,281 34.04% 2026-06-30
Muneer A Satter
Director · +120,000 options
Insider 10,342,134 26.82% 2026-05-28
STATE STREET CORPORATION Institution (13G, 5%+) 9,824,321 25.48% 2026-06-30
BVF Inc. Institution (13F) 8,278,164 21.47% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 7,870,677 20.41% 2026-09-30
MAK Capital One LLC Institution (13F) 7,769,003 20.15% 2026-09-30
Ameriprise Financial, Inc. Institution (13F) 5,998,958 15.56% 2026-09-30
Bain Capital Life Sciences Investors, LL Institution (13F) 4,437,731 11.51% 2026-09-30
Siren, L.L.C. Institution (13F) 4,359,560 11.30% 2026-09-30
Douglas Love
PRESIDENT AND CEO, Director · +2.55M options
Insider 390,476 1.01% 2026-09-24

Share count 38,563,565 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-09-24
filed 2026-09-25
Love Douglas
Purchase (P) 26,065 $3.83 390,476
2026-08-10
filed 2026-08-12
Blumenkranz Mark S.
Option award (A) 175,000 – –
2026-06-11
filed 2026-06-15
Cockroft Bettina M.
Option award (A) 65,000 – –
2026-06-11
filed 2026-06-15
Carson William H.
Option award (A) 65,000 – –
2026-06-11
filed 2026-06-15
Yednock Ted
Option exercise (M) 30,646 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full ANNX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ANNX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.